GLP-1 news · November 9, 2026
Hims & Hers Q3 2026: revenue up 49% to $890 million as subscribers dip
Hims & Hers reported Q3 2026 revenue of $890.4 million on Nov 9, up 49%. Subscribers were 2.79 million, below June, and it narrowed its 2026 revenue outlook.
Hims & Hers Health reported third-quarter 2026 results on November 9, 2026, in a filing with the SEC. Revenue was $890.4 million, up 49% from $599.0 million a year earlier and inside the $880 million to $900 million range the company gave in August. US revenue rose 21% to $657.1 million, and revenue outside the US more than quadrupled to $233.3 million.
Subscribers ended the quarter at 2.788 million, up 13% from a year earlier but below the 2.891 million the company reported at the end of June. Monthly revenue per average subscriber rose to $105 from $81. Gross margin fell to 57% from 74%, and the company posted a net loss of $33.0 million.
The release repeats the change Hims made to its US weight loss business in the first quarter: it now focuses on access to branded GLP-1 medications and offers compounded GLP-1s on its platform only on a limited scale. Compounded drugs are not FDA-approved.
Hims narrowed its 2026 revenue outlook to $3.13 billion to $3.15 billion, from $3.1 billion to $3.3 billion in August, and lowered its adjusted EBITDA outlook to $257 million to $277 million. The release does not mention the lawsuit brought by the FTC, California and Utah, which Hims asked a federal court to dismiss on October 22.
What this means for you
- If you joined Hims or Hers for compounded semaglutide, ask whether your plan has moved to a branded drug and what it now costs. Our Hers review lists current prices.
- Membership fees and drug prices are separate at Hims and Hers; compare full monthly totals on our cheapest GLP-1 online list.
- The FTC case is unresolved; read the cancellation terms before you sign up.
Source: Hims & Hers Health Form 8-K, Exhibit 99.1, November 9, 2026.
Chia Health
Our #1 pick for GLP-1 weight loss online
- One monthly price: clinician, medication and free shipping included
- Semaglutide or tirzepatide, as a weekly injection or a daily tablet
- No insurance needed; HSA/FSA and Klarna accepted
Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure
$212.89 first month, then $349/mo
6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.
We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.